Home > News > Show information

Global pharmaceutical industry market size and competitive landscape analysis in 2021(1)

2021-07-06 16:54:06 JE Read



In recent years, the rapid development of the global pharmaceutical market, global drug sales in 2020 is estimated to reach 1.4 trillion U.S. dollars, an increase of 7.7% year-on-year. North America is still the main market, Africa, Asia (except Japan and Australia) region, the global drug sales revenue share of the trend of year-on-year growth.


For the pharmaceutical industry, research and development investment is one of the main factors influencing pharmaceutical R&D output, global R&D investment will rise to $19.5 billion in 2021. The largest investment is Roche totaling $13.9 billion; R & D investment accounted for the largest revenue ratio is Merck's highest investment in R & D, accounting for 28.30 percent.


The main listed companies in the pharmaceutical industry: At present, the main listed companies in the domestic pharmaceutical industry are North China Pharmaceutical (600812), HaPharma (600664), Lu Anti-Pharmaceutical (600789), Kolon Pharmaceutical (002422), Kehua Biological (002022), etc.


Core data of this article: global market size, global market pattern, global R&D expenditure, R&D investment amount TOP10 companies, R&D investment ratio TOP10 companies


1, global scale year by year, Africa, Southeast Asia, etc. become the main driving force


In recent years, the rapid development of the global pharmaceutical market is mainly due to two aspects: on the one hand, the patents of some major drugs will expire one after another, so that more generic drugs can enter the market; on the other hand, the rapid economic growth of emerging countries has boosted the demand for drugs in these countries.


Before the global financial crisis, with the development of global economic integration and the increasing degree of aging of the global population, global drug sales have been increasing, and between 2003 and 2009, global drug sales have always maintained a growth rate of more than 7%.


Since 2012, the deep impact of the international financial crisis continues, the global economic recovery has not seen a significant improvement, but due to the entry of financial capital to promote the growth of drug demand and improved access to medical care, global drug sales began to achieve restorative growth, the growth rate gradually increased, with the number of patent expiration of drugs fell sharply, innovative drugs emerged and prices rose, as of 2019, global drug Sales are expected to reach $1.30 trillion by 2019, an increase of 4.8 percent compared to 2018. According to preliminary estimates by IMS, global drug sales are estimated to reach $1.4 trillion in 2020, an increase of 7.7 percent year-on-year.


According to IMS forecasts, total pharmaceuticals consumed globally will grow at a rate of 3 percent per year through 2021, slightly above demographic changes and demographic shifts, but with different drivers of growth around the world. Drug spending will grow by 4-7%, driven primarily by new drug launches in mature markets and increased drug usage in emerging markets.


Mature markets will offset the increased costs of using new drugs through the use of generics and focus more on pricing and accessibility measures, while emerging markets seek to achieve the expansion in accessibility that was promised when their economic outlook strengthened. By 2021, global drug spending based on invoice prices will approach $1.5 trillion. Emerging markets such as Southeast and East Asia, Africa and South Asia are expected to grow at a compound annual growth rate of more than 10 percent, making them a major driving force in the global pharmaceutical industry.


From Statista's data, it can be seen that the market share of North America has been maintained at more than 40% from 2010 to 2020, with a preliminary estimate of 51.1% market share in 2020. Next is the European market, market share has been maintained at more than 20%, but in recent years the trend of shrinkage, the market share in 2020 is expected to be 20.6%; Africa, Asia (except Japan and Australia) region, the global drug sales revenue accounted for the trend of year-on-year growth.